This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Saskatchewan directory, so their courses may be missing. Find their university profile.
Research
Latest papers
An ultralow-background far-red light-responsive optogenetic tool based on an engineered biliverdin-binding domain.
Nature methods · 2026
Efficacy of actinium-225-labeled fully human anti-MUC-16 radioimmunoconjugate against MUC-16-positive ovarian and pancreatic ductal adenocarcinoma xenograft models.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
Efficacy of a site-specific anti-Nectin-4 antibody-drug conjugate against Nectin-4-positive triple-negative breast cancer models.
International journal of pharmaceutics · 2026
Latest funding
- $979,200
Priming MUC-16 positive ovarian and pancreatic cancer cells for immunotherapy using an alpha particle labeled radioimmunoconjugate
CIHR · 2023 · Principal investigator
- $62,500
225Ac-labeled anti-nectin-4 radioimmunoconjugate with/without immune checkpoint blockage in triple negative breast cancer.
CIHR · 2023 · Co-investigator
- $60,000
Development of molecular imaging probes targeting Nectin4 (PVRL4) expression in cancer
CIHR · 2021 · Nominated PI
26 publications.
An ultralow-background far-red light-responsive optogenetic tool based on an engineered biliverdin-binding domain.
Le GNT, Pham LMT, Xue B, Uppalapati M, Woolley GA
Efficacy of actinium-225-labeled fully human anti-MUC-16 radioimmunoconjugate against MUC-16-positive ovarian and pancreatic ductal adenocarcinoma xenograft models.
Babeker H, Nwangele E, Monzer A, Pougoue Ketchemen J, Bato KE, Njotu FN, Tikum AF, Mercado T, Doroudi A, Torlakovic E, Gordon JR, Uppalapati M, Fonge H
Efficacy of a site-specific anti-Nectin-4 antibody-drug conjugate against Nectin-4-positive triple-negative breast cancer models.
Njotu FN, Garcia MD, Nwangele E, Babeker H, Pougoue Ketchemen J, Doroudi A, Price EW, Gordon JR, Uppalapati M, Fonge H
Red-Light-Only Control of Protein-Protein Interactions Using a Cyanobacteriochrome (UNICYCL).
Le GNT, Reed PMM, Jang J, Tang K, Zurbriggen MD, Uppalapati M, Woolley GA
[225Ac]Ac-labeled matuzumab is an effective radioimmunotherapeutic against EGFR-positive triple negative breast cancer.
Tikum AF, Fon DA, Njotu FN, Henning N, Nwangele E, Babeker H, Ketchemen JP, Doroudi A, Uppalapati M, Fonge H
Optimized Phage Display-Based Selection for the Development of Heterodimerizing Optogenetic Tools.
Le GNT, Jang J, Uppalapati M, Woolley GA
An Anti-EGFR Antibody-Drug Radioconjugate Labeled with Actinium-225 Elicits Durable Antitumor Responses in KRAS- and BRAF-Mutant Colorectal Cancer.
Tikum AF, Henning NW, Pougoue Ketchemen J, Doroudi A, Babeker H, Njotu FN, Nwangele E, Monzer A, Gray B, Torlakovic E, Uppalapati M, Fonge H
225Ac/89Zr-Labeled N4MU01 Radioimmunoconjugates as Theranostics Against Nectin-4-Positive Triple-Negative Breast Cancer.
Babeker H, Njotu FN, Pougoue Ketchemen J, Monzer A, Tikum AF, Doroudi A, Nwangele E, Uppalapati M, Fonge H
Effects of binding partners on thermal reversion rates of photoswitchable molecules.
Reed PMM, Jang J, Woloschuk RM, Reis J, Hille JIC, Uppalapati M, Woolley GA
Preclinical safety and effectiveness of a long-acting somatostatin analogue [225Ac]Ac-EBTATE against small cell lung cancer and pancreatic neuroendocrine tumors.
Njotu FN, Pougoue Ketchemen J, Babeker H, Henning N, Tikum AF, Nwangele E, Monzer A, Hassani N, Gray BD, Pak KY, Torlakovic EE, Uppalapati M, Fonge H
Priming MUC-16 positive ovarian and pancreatic cancer cells for immunotherapy using an alpha particle labeled radioimmunoconjugate
Principal investigators: Fonge, Humphrey A; Uppalapati, Maruti
Keywords: Actinium-225; Antibody Drug Conjugates; Immune Checkpoint Inhibitors; Micropet/Ct Imaging; Muc-16; Ovarian Cancer; Pancreatic Cancer; Precision Medicine; Radioimmunotherapy; Theranostics
225Ac-labeled anti-nectin-4 radioimmunoconjugate with/without immune checkpoint blockage in triple negative breast cancer.
Principal investigators: Fonge, Humphrey A
Keywords: Chemotherapy And Radiotherapy; Imaging Technologies; Immunotherapy
Development of molecular imaging probes targeting Nectin4 (PVRL4) expression in cancer
Principal investigators: Uppalapati, Maruti
Keywords: Imaging Technologies; Translational Research
Optogenetic gap junctions - tools to allow control of tissue patterning.
Principal investigators: Woolley, Andrew
Developing radioimmunotherapy of osteosarcoma using comparative oncology approach
Principal investigators: Dadachova, Ekaterina; Uppalapati, Maruti
Keywords: 177lutetium; Companion Dogs With Osterosarcoma; Human Antibodies; Immunohistochemistry; Insulin Growth Factor Type 2 Receptor; Mouse Models; Non-Invasive Pet And Spect/Ct Imaging; Ostersarcoma; Radioimmunotherapy; Safety Studies
Small protein-domain affinity reagents and D-proteins
Principal investigators: Uppalapati, Maruti
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Medical Imaging
- Pathology and Laboratory Medicine
- Oncology
- Chemistry
- Other
Co-authors at University of Saskatchewan, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
Humphrey Fonge
Medical Imaging
7 shared papers, latest 2026
Humphrey Fonge
Faculty
6 shared papers, latest 2026
Ekaterina Dadachova
Pathology and Laboratory Medicine
5 shared papers, latest 2024
Andrew Freywald
Oncology
2 shared papers, latest 2019
Maruti Uppalapati
Chemistry
1 shared papers, latest 2025
Maruti Uppalapati
Faculty
1 shared papers, latest 2025
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.